Background
Japanese reexamination system was inaugurated, ahead of the world, in April 1980 when the amendment of Pharmaceutical Affairs Law (PAL) in October 1979 was enforced. The aim of the reexamination system was to reconfirm the quality, effectiveness and safety of new drugs and medical devices using the new information accumulated after the approval of the products. The importance of the reexamination system is currently increasing as the number of drugs with new pharmacological mechanisms and indications for rare diseases and special patient populations has increased in recent years, while the safety information for those products available before the approval is often limited. In addition, it is not rare that a new drug is marketed at the same time in the world and some drugs may be marketed in Japan for the first time in the world under the new "sakigake" strategy. What was aimed in the reexamination system when it was started in 1980 is still appropriate at the present time. Nevertheless, in general, any system can become truly useful or lose substance depending on how it is operated. Under the recognition that the current Japanese pharmacovigilance practice is facing various problems as mentioned below, and its underlying cause is in the inappropriate operation of the reexamination system, we have decided to publish our proposals for a change.
Emerging problems
 ICH-E2E "Pharmacovigilance Planning", which was issued as a notification (September 16, 2005) No. 0916001 by Director, Evaluation and Licensing Division and No. 0916001 by Director, Safety Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare (MHLW), provided key methods to help the industry select the way to address individual problems summarized by the Safety Specification. However, neither the industry nor the regulatory body was serious about implementing ICH-E2E; to date, ICH-E2E has been a "forgotten document". notifications do not have a concept of comparison. Without comparison, the evaluation of the causality of adverse events is virtually impossible except when the background incidence is negligibly small.  In the "RMP notification" which is now stipulated in the amendment of another ministerial ordinance "Good Vigilance Practice (GVP)", the industry is required to summarize the important identified risks of a drug, important potential risks, and important missing information in the Safety Specification. Nevertheless, in almost all RMPs so far submitted by pharmaceutical industries, the traditional "drug use results surveys" or the "specific use results surveys" are selected as a research tool to address the problems specified in the Safety Specification because the GPSP ordinance requires that the industry should normally select these traditional methods. In other words, two ministerial ordinances (GPSP and GVP) are poorly connected with each other.
Other types of emerging problems include ineffective use of the new development of conditions and potential resources which may help the appropriate operation of the reexamination system. These include the following.
 Since 1996 when Japanese Society for Pharmacoepidemiology (JSPE) was established, JSPE has tried to encourage the use of pharmacoepidemiology in the society and published several proposals and has been involved in the enlightenment activities to meet this end. From 2012, JSPE started the certification system for "pharmacovigilance specialist" to foster human resources. In addition, thanks to the creation of several departments and schools of universities to teach epidemiology, including pharmacoepidemiology, and the continued efforts over the years of a few incorporated foundations to foster human resources, the number of individuals who have certain level of knowledge of pharmacoepidemiology is gradually increasing, although still insufficient in number. The current reexamination system, however, impedes epidemiologically sound inputs from these precious human resources to be reflected in organizational actions, with a consequence that proper involvement of these individuals being rare in designing and conducting studies in the reexamination system.  Despite the emergence of the big data and real world data related to the medical services, no consensus has been reached about the proper use of medical databases in the reexamination system. This is due to difficulty in positioning such use under the current regulations governing the reexamination system (Note 2).
(Note 2) In general, a database study can provide good evidence leading to the good decision making in safety measures. Nevertheless, when the indices for the outcome and other key variables are not well validated or the information of key variables is not confirmed by the source documents, a database study may be regarded merely as a screening tool to judge whether the next action, including conducting a study involving primary data collection, is needed.
Underlying cause
The emerging problems outlined in the above section represent the end results derived from the underlying cause. The underlying cause of the malfunction of pharmacovigilance practice is the inappropriate operation of the reexamination system which should be changed to create an enabling environment in Japan for contributing to the worldwide proper use of drugs. Figure 1 depicts the current structure of the regulation of pharmacovigilance in Japan. Ministerial Ordinance "amendments of the GVP and GPSP ordinances"
The Pharmaceutical and Medical Device Act (PMD Act, former PAL) stipulates the reexamination of newly marketed drugs in Article 14-4. The following descriptions are given in Articles 14-4(2)4 and 14-4(2)6 (The underline was given by the authors of the current proposals).
Pharmaceutical and Medical Device Law (PMD Law) Article 14-4(2)4 The applications specified in Paragraph 1 shall be made by means of an application form with data concerning the results of use of the drug and other data specified by MHLW ordinance attached. When the drug concerned in such applications is specified by MHLW ordinance, the data concerned must be collected and compiled in accordance with standards specified by MHLW Ordinance. The GPSP ordinance and related notifications are the root causes of the malfunctioned operation of the reexamination system in Japan.
In the GPSP ordinance, only three study designs are mentioned as methods to investigate "the results of use, etc." in the PMD Law, namely, "drug use results survey", "specific use results survey" and "post-marketing clinical studies". This practically limits the available options. To limit the options for the post-marketing studies to these three is not compatible with what ICH-E2E requires where it is clearly stated that "the best method to address a specific situation can vary depending on the product, the indication, the population being treated and the issue to be addressed" in Section 3.2. All the related notifications presuppose that only these three options, but no other methods, are available for the studies in the reexamination system, thereby strengthen the narrow view of the GPSP ordinance. Desired study designs for studies in the RMP under the GVP ordinance are not compatible with "post-marketing surveillance" in the GPSP ordinance. It has been already pointed out many times by several authors that virtually no useful information has been generated from the current studies conducted by drug companies using the traditional "drug use results survey" and "specific use results survey" designs stipulated in the GPSP ordinance, which lack the critical concept of comparison.
Proposals
Based on the above observations, we present the following proposals to help develop a good pharmacovigilance planning to achieve the good pharmacovigilance system and resultant good safety measures in Japan.
[Proposal 1] The GPSP ordinance should be completely revised to encourage referring the annex "pharmacovigilance methods" in "Pharmacovigilance planning" (issued as a notification of No 0916001, September 16, 2005) and not to limit the methods for pharmacovigilance and studies for generating evidence to certain types of designs (Note 3).
(Note 3) All the notifications related to the GPSP ordinance should be revised.
Several measures such as organizing expert groups to examine the problems of the current regulation may be needed to achieve the full range of revision of all the related notifications. It is beyond the scope of the current proposals to present the full range of the required changes to these notifications.
[Proposal 2] The GVP ordinance provides the standards for the safety management in the post-marketing phase, including the early post-marketing phase vigilance (EPPV).
The EPPV, mentioned in the annex of "pharmacovigilance planning" may be maintained in the future. However, the use of this scheme should be restricted to the epoch-making drugs marketed at the same time in the world or marketed for the first time in Japan. In such a situation, the EPPV may detect a new risk for the first time in the world. Early post-marketing phase vigilance (EPPV) will be conducted for 6 months, and additional post-marketing vigilance activities will be considered if the specified number of reports is exceeded.
Jan. 1, 2016
Serious mental condition (potential risk)
Will PMS be conducted? (■ No □ Yes [□ Surveillance study □ Clinical study]) EPPV will be conducted for 6 months, and additional post-marketing vigilance activities will be considered if the specified number of reports is exceeded.
Anaphylactic shock (potential risk)
Will PMS be conducted? (■ No □ Yes [□ Surveillance study □ Clinical study]) EPPV will be conducted for 6 months, and additional post-marketing vigilance activities will be considered if the specified number of reports is exceeded. (1) Surveillance study design title/name (Examples: Cohort study, case control study, self-controlled design) (2) Surveillance study objectives A. Hypothesis for confirmation/verification B. Outcome measures (3) Background for formulation of surveillance study design A. Results of surveillance studies conducted overseas and associated published reports and missing information B. Level of urgency until surveillance study results are obtained C. Feasibility (including, for example, the burden place on the health care setting and the ethical difficulties of therapeutic intervention) (4) Data source (e.g., primary data newly obtained by the surveillance study, medical database) (5) Definition of target patient population A. Primary target patient population (e.g., patients treated with the drug product) B. Comparative controls (not needed if the surveillance study is not going to include control group) (6) Number of subjects to be studied, observation period, and rationales A. Primary target population B. Comparative control group C. Observation period (for a self-controlled design, the relationship to the treatment period should be clearly noted) (7) Number of sites expected to conduct the surveillance study (and, if a medical database is going to be used secondarily, then the scale of the medical database) (8) Expected surveillance study timeline (9) Outcome identification method (including whether or not existing medical data will be used, and the establishment of an event review committee) (10) Analysis A. Overview of analysis methods B. If a sensitivity analysis is going to be conducted and, if so, the details thereof (11) Surveillance study limitations (e.g., potential discrepancies between the information that is truly desired and the information that can be obtained by conducting the surveillance study) (12) Organizational structure for conducting the surveillance study (If a part of the surveillance study activities are going to be outsourced, then the name and address of the party to which activities are going to be outsourced, and the scope of the activities being outsourced) (13) Assurance of transparency/scientific appropriateness (e.g., advance protocol registration/involvement of third parties) (14) 
